Search
Fingolimod
go.drugbank.com/drugs/DB08868ApprovedInvestigationalIt was developed by Novartis and initially approved by the FDA in 2010.[L12651] Fingolimod was also studied for the treatment of COVID-19, the disease caused by infection with the SARS-CoV-2 virus.
Oxaprozin
go.drugbank.com/drugs/DB00991ApprovedOxaprozin is a non-narcotic, non-steroidal anti-inflammatory drug (NSAID), used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis.
Categories: Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Analgesics, Non-NarcoticIdursulfase
go.drugbank.com/drugs/DB01271ApprovedInvestigationalIdursulfase is produced by recombinant DNA technology in a human cell line. … The enzyme contains eight asparagine-linked glycosylation sites occupied by complex oligosaccharide structures.
Methimazole
go.drugbank.com/drugs/DB00763ApprovedInvestigational[A184733] Traditionally, methimazole has been preferentially used over propylthiouracil due to the risk of fulminant hepatotoxicity carried by the latter,[A184757] with propylthiouracil being preferred … in pregnancy due to a perceived lower risk of teratogenic effects.
Avalglucosidase alfa
go.drugbank.com/drugs/DB16099ApprovedInvestigational[A232960] On August 6, 2021, avalglucosidase alfa-ngpt was approved by the FDA under the market name Nexviazyme to treat patients one year of age and older with late-onset Pompe disease. … Pompe disease is characterized by progressive muscle weakness and loss of motor function, including respiratory muscle weakness, which leads to premature death and debilitating effects on people’s lives
Synonyms: Neo-recombinant human acid alpha-glucosidaseFenbufen
go.drugbank.com/drugs/DB08981ApprovedFenbufen acts by preventing cyclooxygenase from producing prostaglandins which can cause inflammation. … Fenbufen is a non-steroidal anti-inflammatory drug used primarily to treat inflammation in osteoarthritis, ankylosing spondylitis, and tendinitis.
Categories: Analgesics, Non-Narcotic, Non COX-2 selective NSAIDSFremanezumab
go.drugbank.com/drugs/DB14041ApprovedInvestigational[L11749] It was developed by Teva Pharmaceuticals USA and approved by the FDA in September 2018.
Methenamine
go.drugbank.com/drugs/DB06799ApprovedInvestigationalVet approvedMethenamine is a heterocyclic organic compound with a cage-like structure similar to adamantane.
Mixtures: UR N-C Urinary Antiseptic, Non Toxic DisinfectantFosdenopterin
go.drugbank.com/drugs/DB16628ApprovedBy improving the three-year survival rate from 55% to 84%,[L32288] and considering the lack of alternative therapies available, fosdenopterin appears poised to become a standard of therapy in the management … [A230088] Fosdenopterin was approved by the FDA on Februrary 26, 2021, for the reduction of mortality in patients with MoCD type A,[L32163] becoming the first and only therapy approved for the treatment
Risankizumab
go.drugbank.com/drugs/DB14762ApprovedInvestigational[L39885] It gained its first global approval in Japan in March 2019, followed by approval in Canada, the US, and Europe in April 2019. … [A254716] Risankizumab is used to treat plaque psoriasis, psoriatic arthritis, and Crohn's disease.[L39885,L44191,L44231] Risankizumab is being investigated for atopic dermatitis.[A254716]